MCID: KDN017
MIFTS: 60

Kidney Cancer

Categories: Cancer diseases, Nephrological diseases

Aliases & Classifications for Kidney Cancer

MalaCards integrated aliases for Kidney Cancer:

Name: Kidney Cancer 12 42 15
Renal Cancer 12 73 54 15
Renal Carcinoma 17 70
Kidney Neoplasm 17 70
Malignant Neoplasm of Kidney Except Pelvis 12
Malignant Neoplasm of Kidney 70
Malignant Tumour of Kidney 12
Renal Cell Carcinoma 70
Kidney Carcinoma 6
Kidney Neoplasms 44
Cancer, Kidney 39
Cancer, Renal 39

Classifications:



External Ids:

Disease Ontology 12 DOID:263
ICD9CM 34 189.0
MeSH 44 D007680
SNOMED-CT 67 126880001 93849006
ICD10 32 C64
UMLS 70 C0007134 C0022665 C0494158 more

Summaries for Kidney Cancer

MedlinePlus : 42 You have two kidneys. They are fist-sized organs on either side of your backbone above your waist. The tubes inside filter and clean your blood, taking out waste products and making urine. Kidney cancer forms in the lining of tiny tubes inside your kidneys. Kidney cancer becomes more likely as you age. Risk factors include smoking, having certain genetic conditions, and misusing pain medicines for a long time. You may have no symptoms at first. They may appear as the cancer grows. See your health care provider if you notice Blood in your urine A lump in your abdomen Weight loss for no reason Pain in your side that does not go away Loss of appetite Tests to diagnose kidney cancer include blood, urine, and imaging tests. You may also have a biopsy. Treatment depends on your age, your overall health and how advanced the cancer is. It might include surgery, chemotherapy, or radiation, biologic, or targeted therapies. Biologic therapy boosts your body's own ability to fight cancer. Targeted therapy uses drugs or other substances that attack specific cancer cells with less harm to normal cells. NIH: National Cancer Institute

MalaCards based summary : Kidney Cancer, also known as renal cancer, is related to renal cell carcinoma, nonpapillary and clear cell renal cell carcinoma, and has symptoms including flank pain An important gene associated with Kidney Cancer is GAS5 (Growth Arrest Specific 5), and among its related pathways/superpathways are MicroRNAs in cancer and miRNAs involved in DNA damage response. The drugs Nicotine and Bupropion have been mentioned in the context of this disorder. Affiliated tissues include kidney, prostate and bone.

Disease Ontology : 12 A urinary system cancer that is located in the kidney.

Wikipedia : 73 Renal cell carcinoma (RCC) is a kidney cancer that originates in the lining of the proximal convoluted... more...

Related Diseases for Kidney Cancer

Diseases in the Kidney Cancer family:

Kidney Carcinoma in Situ

Diseases related to Kidney Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 718)
# Related Disease Score Top Affiliating Genes
1 renal cell carcinoma, nonpapillary 31.6 PVT1 MIR27A MIR210 MIR21 MIR200C MIR17
2 clear cell renal cell carcinoma 31.1 PVT1 MIR210 MIR21 MIR200C MIR126 MIR106B
3 thyroid carcinoma 30.7 PVT1 MALAT1 HOTAIR H19 GAS5
4 neuroblastoma 30.6 MIR21 MIR17 MEG3 MALAT1 HOTAIR H19
5 bladder cancer 30.5 RNY3 RNY1 PVT1 MIR21 MIR17 MIR141
6 leukemia, chronic myeloid 30.2 MIR17 MIR126 MEG3 HOTAIR H19
7 microvascular complications of diabetes 3 30.2 PVT1 MIR21 MALAT1
8 osteogenic sarcoma 30.2 PVT1 MEG3 MALAT1 HOTAIR HIF1A-AS2 H19
9 lipoprotein quantitative trait locus 30.2 MIR27A MIR21 MIR17 MIR126 H19 GAS5
10 laryngeal squamous cell carcinoma 30.2 MIR21 MALAT1 HOTAIR H19
11 pituitary adenoma 30.2 MEG3 MALAT1 HOTAIR H19
12 gallbladder cancer 30.2 MEG3 MALAT1 HOTAIR H19
13 heart valve disease 30.2 MIR21 MIR17 MIR126
14 lung cancer susceptibility 3 30.2 MIR21 MIR200C MIR17 MIR126 MEG3 MALAT1
15 osteoarthritis 30.1 MEG3 HOTAIR H19 GAS5
16 pulmonary disease, chronic obstructive 30.1 MIR21 MIR17 MIR126 MEG3
17 malignant pleural mesothelioma 30.1 PVT1 MIR17 GAS5
18 b-cell lymphoma 30.1 PVT1 MIR21 MIR17 MALAT1 HOTAIR GAS5
19 bladder urothelial carcinoma 30.1 PVT1 MEG3 MALAT1 HOTAIR GAS5
20 arteries, anomalies of 30.0 MIR27A MIR210 MIR21 MIR17 MIR141 MIR126
21 diffuse large b-cell lymphoma 30.0 MIR27A MIR210 MIR21 MIR17 MIR126 HOTAIR
22 melanoma 30.0 PVT1 MIR27A MIR210 MIR200C MIR17 MIR141
23 glioblastoma 30.0 MIR210 MIR21 MEG3 MALAT1 HOTAIR HIF1A-AS2
24 peripheral nervous system disease 29.9 MIR27A MIR21 MIR17 MIR126
25 glioma 29.9 PVT1 MIR210 MIR21 MIR17 MEG3 MALAT1
26 connective tissue disease 29.9 MIR27A MIR210 MIR21 MIR17 MIR126
27 pancreas disease 29.9 MIR27A MIR21 MIR200C MIR17 MIR141 MIR126
28 diabetes mellitus 29.9 PVT1 MIR27A MIR210 MIR17 MIR126 MEG3
29 leukemia, acute lymphoblastic 29.9 MIR27A MIR210 MIR21 MIR17 MIR126
30 myeloma, multiple 29.9 PVT1 MIR27A MIR21 MIR17 MIR126 MIR106B
31 leukemia, chronic lymphocytic 29.9 MIR27A MIR21 MIR17 MIR141 MIR126 MIR106B
32 oral squamous cell carcinoma 29.8 MIR27A MIR21 MIR200C MIR17 MIR126 MEG3
33 leukemia, acute myeloid 29.7 MIR27A MIR210 MIR21 MIR17 MIR126 MIR106B
34 prostate disease 29.7 MIR27A MIR21 MIR17 MIR141 MIR126 MIR106B
35 cervical cancer 29.7 RNY3 RNY1 PVT1 MIR21 MIR17 MIR126
36 esophageal cancer 29.6 PVT1 MIR21 MIR200C MIR141 MIR126 MEG3
37 pancreatic cancer 29.5 PVT1 MIR210 MIR21 MIR200C MIR17 MIR141
38 breast cancer 29.4 PVT1 MIR27A MIR210 MIR21 MIR200C MIR17
39 prostate cancer 29.4 RNY3 RNY1 PVT1 MIR27A MIR210 MIR21
40 ovarian cancer 29.4 PVT1 MIR27A MIR210 MIR21 MIR200C MIR17
41 hepatocellular carcinoma 29.4 PVT1 MIR27A MIR210 MIR21 MIR17 MIR141
42 gastric cancer 29.3 PVT1 MIR27A MIR21 MIR200C MIR17 MIR141
43 lung cancer 29.2 RNY3 RNY1 PVT1 MIR27A MIR210 MIR21
44 colorectal cancer 29.1 RNY3 RNY1 PVT1 MIR27A MIR21 MIR200C
45 hereditary leiomyomatosis and renal cell cancer 11.2
46 inherited renal cancer-predisposing syndrome 11.1
47 chromophobe renal cell carcinoma 11.1
48 wilms tumor 1 11.1
49 von hippel-lindau syndrome 11.1
50 kidney benign neoplasm 11.0

Graphical network of the top 20 diseases related to Kidney Cancer:



Diseases related to Kidney Cancer

Symptoms & Phenotypes for Kidney Cancer

UMLS symptoms related to Kidney Cancer:


flank pain

Drugs & Therapeutics for Kidney Cancer

Drugs for Kidney Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 416)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Nicotine Approved Phase 4 54-11-5 942 89594
2
Bupropion Approved Phase 4 34841-39-9, 34911-55-2 444
3
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 4 437-38-7 3345
4
Bupivacaine Approved, Investigational Phase 4 2180-92-9, 38396-39-3 2474
5
Ropivacaine Approved Phase 4 84057-95-4 71273 175805
6
Dexmedetomidine Approved, Vet_approved Phase 4 113775-47-6 5311068 68602
7
Lidocaine Approved, Vet_approved Phase 4 137-58-6 3676
8
Papaverine Approved, Investigational Phase 4 61-25-6, 58-74-2 4680
9 Neurotransmitter Agents Phase 4
10 Psychotropic Drugs Phase 4
11 Central Nervous System Stimulants Phase 4
12 Cholinergic Agents Phase 4
13 Nicotinic Agonists Phase 4
14 Platelet Aggregation Inhibitors Phase 4
15 Antidepressive Agents Phase 4
16 Dopamine Agents Phase 4
17 Cytochrome P-450 Enzyme Inhibitors Phase 4
18 Dopamine Uptake Inhibitors Phase 4
19 Adrenergic alpha-Agonists Phase 4
20 Adrenergic Agonists Phase 4
21 Adrenergic Agents Phase 4
22 Hypnotics and Sedatives Phase 4
23 Anesthetics Phase 4
24 Anesthetics, Local Phase 4
25 Analgesics, Opioid Phase 4
26 Sodium Channel Blockers Phase 4
27 Diuretics, Potassium Sparing Phase 4
28 Phosphodiesterase Inhibitors Phase 4
29 interferons Phase 4
30 Hydroxyethyl Starch Derivatives Phase 4
31 Plasma Substitutes Phase 4
32 Blood Substitutes Phase 4
33
Mannitol Approved, Investigational Phase 3 69-65-8 6251 453
34
tannic acid Approved Phase 2, Phase 3 1401-55-4
35
Benzocaine Approved, Investigational Phase 2, Phase 3 1994-09-7, 94-09-7 2337
36
Clonidine Approved Phase 2, Phase 3 4205-90-7 2803
37
Thalidomide Approved, Investigational, Withdrawn Phase 3 50-35-1 5426
38
Peginterferon alfa-2a Approved, Investigational Phase 2, Phase 3 198153-51-4 5360545
39
Diphenhydramine Approved, Investigational Phase 3 58-73-1, 147-24-0 3100
40
Promethazine Approved, Investigational Phase 3 60-87-7 4927
41
Medroxyprogesterone acetate Approved, Investigational Phase 3 71-58-9
42
Sulfamethoxazole Approved Phase 3 723-46-6 5329
43
Trimethoprim Approved, Vet_approved Phase 3 738-70-5 5578
44
Thrombin Approved, Investigational Phase 3
45
nivolumab Approved Phase 3 946414-94-4
46
Everolimus Approved Phase 3 159351-69-6 6442177 70789204
47
Ipilimumab Approved Phase 3 477202-00-9
48
Minocycline Approved, Investigational Phase 3 10118-90-8 5281021
49
Denosumab Approved Phase 3 615258-40-7
50
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978

Interventional clinical trials:

(show top 50) (show all 1483)
# Name Status NCT ID Phase Drugs
1 The Use of Self Retaining Sutures in Open and Laparoscopic Partial Nephrectomy Unknown status NCT01413607 Phase 4
2 Study to the Optimal Duration of Therapy With Oral Angiogenesis Inhibitors Unknown status NCT00777504 Phase 4 usage oral angiogenesis inhibitor;stop oral angiogenesis inhibitor
3 Everolimus (Afinitor) in Patients With Metastatic Renal Cell Carcinoma Following Progression on Prior Bevacizumab Treatment Completed NCT02056587 Phase 4 Everolimus
4 Comparing the Lozenge to the Patch for Smoking Cessation Completed NCT00365508 Phase 4 nicotine lozenge;nicotine patch
5 Enhancing Tobacco Use Treatment for African American Light Smokers Completed NCT00666978 Phase 4 bupropion hydrochloride
6 Interleukin-2 In An Alternative Dose (The Iliad Trial): Treatment Of Patients With Metastatic Renal Cell Carcinoma With Low Dose Proleukin Completed NCT00006864 Phase 4
7 Evaluation of Cardiac Arrhythmias in Patients Undergoing Kidney Cancer Surgery Depending on the Anaesthesia Method Completed NCT02988219 Phase 4 Bupivacaine-fentanyl
8 Immunomodulatory Effects of Volatile and Total Intravenous Anesthesia for Patients With Renal Cancer Completed NCT03514550 Phase 4 Propofol;Sevoflurane
9 An Open Label, Single Arm Trial to Characterize Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of the First VEGF-targeted Therapy Completed NCT01266837 Phase 4 Everolimus
10 An Open-label, Multi-center Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for Patients With Metastatic Recurrent and/or Unresectable Renal Cell Carcinoma (EVERMORE). Completed NCT01206764 Phase 4 RAD001
11 A Single Arm Multicentre Study Evaluating Pazopanib in First-line Treatment of Poor-risk Patients With Locally Advanced or Metastatic Renal Cell Carcinoma Completed NCT01521715 Phase 4 Pazopanib
12 An Open Label, Single Arm Trial to Evaluate Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of First Line Therapy With Sunitinib or Pazopanib Completed NCT01514448 Phase 4 Everolimus (RAD001)
13 Therapeutic Drug Monitoring of Sunitinib and Pazopanib in Advanced or Metastatic Renal Cell Carcinoma Completed NCT02555748 Phase 4 Pazopanib;Sunitinib
14 A Single-Arm, Open-Label, Multi-Center, Phase Iv, Safety And Efficacy Study Of Sunitinib Malate As First-Line Systemic Therapy In Chinese Patients With Metastatic Renal Cell Carcinoma (Post Approval Commitment Study) Completed NCT00706706 Phase 4 Sunitinib Malate (SU011248)
15 Safety Study of Nivolumab for Selected Advanced Malignancies in India Completed NCT03444766 Phase 4 Nivolumab
16 Effects of Dexmedetomidine on Periprocedural Pain During Radiofrequency Ablation of Liver and Kidney Tumours Completed NCT02016391 Phase 4 Dexmedetomidine
17 A Prospective, Randomized, Double-Blinded, Placebo-Controlled Clinical Trial Evaluating the Use of Perioperative Intravenous Lidocaine Infusion to Decrease Pain Scores and Opioid Consumption After Robotic-Assisted Prostatectomy and Robotic-Assisted Partial Nephrectomy Recruiting NCT03824808 Phase 4 Lidocaine Hydrochloride 0.8% in Dextrose 5% Solution;0.9% Sodium Chloride Injection
18 Effect of Papaverine on Intraoperative Renal Artery Blood Flow Volume in Patients Undergoing Robot-assisted Partial Nephrectomy : a Randomized, Placebo-controlled Study Recruiting NCT04162834 Phase 4 Papaverine;Normal saline
19 ICE-SECRET PROSENSE™ Cryotherapy For Renal Cell Carcinoma Trial Recruiting NCT02399124 Phase 4
20 Phase 3b/4 Safety Trial of Nivolumab Combined With Ipilimumab in Subjects With Previously Untreated, Advanced or Metastatic RCC (CheckMate 920: CHECKpoint Pathway and nivoluMAb Clinical Trial Evaluation 920) Active, not recruiting NCT02982954 Phase 4 Nivolumab;Ipilimumab
21 A Phase 3b/4 Safety Trial of Nivolumab (BMS-936558) in Subjects With Advanced or Metastatic Renal Cell Carcinoma (CheckMate 374: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation 374) Active, not recruiting NCT02596035 Phase 4 Nivolumab
22 A Phase 4 Study of Nivolumab in Combination With Ipilimumab in Patients With Previously Untreated Advanced Renal Cell Carcinoma and Intermediate-or Poor-risk Factors Conducted in India Not yet recruiting NCT04513522 Phase 4
23 Effect of Hydroxyethyl Starch on Renal Handling of Salt and Water, Blood Pressure-regulating Hormones, Proteins and Circulatory System of Patients Undergoing Kidney Removal by Keyhole Surgery Terminated NCT01486550 Phase 4 Voluven (Hydroxyethyl starch 130/0,4);Sodium Chloride 9mg/ml
24 Outcome-related Factors in Patients With Metastatic Renal Cell Carcinoma Treated With Everolimus After Failure of a First-line Treatment With VEGF Inhibitor Terminated NCT02338570 Phase 4 Everolimus
25 A Study of Biological, Pathological and Imagery Markers in the First-line Treatment of Metastatic Clear-cell Renal Cell Carcinoma With Sunitinib BEFORE and AFTER Nephrectomy Terminated NCT00930345 Phase 4 Sunitinib (SUTENT)
26 A Proof of Concept Study to Evaluate the Use of Metabonomics and Lipidomics in Predicting Toxicity and Efficacy of Anti-VEGF Therapy in Patients With Metastatic Clear Cell Renal Cell Carcinoma Terminated NCT02570789 Phase 4 patients with sunitinib or pazopanib
27 A Randomized Discontinuation Trial to Determine the Clinical Benefit of Continuation of Sorafenib Following Disease Progression in Patients With Advanced Renal Cell Carcinoma Terminated NCT00352859 Phase 4 Nexavar (Sorafenib, BAY43-9006) with addition of gemcitabine or interferon;Gemcitabine or Interferon (only)
28 Randomized Comparison of Sequential Therapies With Sunitinib and Sorafenib in Advanced Renal Cell Carcinoma Unknown status NCT01481870 Phase 3 Sorafenib-sunitinib;Sunitinib-sorafenib
29 Effects of Physical Activity on the Endothelial and Cardiac Function of Patients With Renal Cell Carcinoma Receiving a Thyrosine Kinase Inhibitor (Sunitinib) Unknown status NCT00869011 Phase 3
30 Randomized Phase III Trial Comparing Immediate Versus Deferred Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Unknown status NCT01099423 Phase 3
31 Nephroblastoma (Wilms Tumour) Clinical Trial And Study Unknown status NCT00047138 Phase 3 carboplatin;cyclophosphamide;doxorubicin hydrochloride;etoposide;vincristine sulfate
32 Nephroblastoma Clinical Trial and Study Unknown status NCT00003804 Phase 3 vincristine sulfate
33 A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects With Metastatic Renal Cell Carcinoma That Has Progressed After Prior VEGFR Tyrosine Kinase Inhibitor Therapy Unknown status NCT01865747 Phase 3 Cabozantinib tablets;Everolimus (Afinitor) tablets
34 Randomized Phase III Trial Evaluating the Importance of Nephrectomy in Patients Presenting With Metastatic Renal Cell Carcinoma Treated With Sunitinib Unknown status NCT00930033 Phase 3
35 Phase 3b, Randomized, Open-Label Study Of Bevacizumab + Temsirolimus Vs. Bevacizumab + Interferon-Alfa As First-Line Treatment In Subjects With Advanced Renal Cell Carcinoma Completed NCT00631371 Phase 3 Bevacizumab;Temsirolimus;Bevacizumab;Interferon-Alfa 9MU
36 A Randomized, Double-blind, Placebo-controlled, Multicenter Phase III Study to Compare the Safety and Efficacy of RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed on VEGF Receptor Tyrosine Kinase Inhibitor Completed NCT00410124 Phase 3 RAD001;Placebo
37 A Randomized Controlled Phase III Adjuvant Trial of High-Dose Bolus IL-2 in Patients With High-Risk Renal Cell Carcinoma Completed NCT00003126 Phase 3 Interleukin-2
38 A Randomised Double-blind Cross-over Patient Preference Study of Pazopanib Versus Sunitinib in Treatment naïve Locally Advanced or Metastatic Renal Cell Carcinoma. Completed NCT01064310 Phase 3 pazopanib;sunitinib
39 A Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of Pazopanib as Adjuvant Therapy for Subjects With Localized or Locally Advanced RCC Following Nephrectomy Completed NCT01235962 Phase 3 pazopanib;placebo;pazopanib;placebo
40 An Open-label Extension Study to Assess the Safety and Efficacy of Pazopanib in Subjects With Renal Cell Carcinoma Previously Enrolled on Protocol VEG105192 Completed NCT00387764 Phase 3 pazopanib
41 Randomized Study of Spinal Anesthesia Compared With Traditional Epidural Anesthesia Concerning Peroperative and Postoperative Pain After Open Nephrectomy in Patients With Renal Cell Carcinoma Completed NCT02030717 Phase 2, Phase 3 klonidin;epidural anesthesia
42 Cytokines in the Treatment of Metastatic Renal Cell Carcinoma (MRCC): Intravenous Interleukin and Subcutaneous Interferon-α Versus Subcutaneous Interleukin and Interferon-α for Good Prognosis Patients [PERCY DUO] Completed NCT00416871 Phase 3
43 Adjuvant Interleukin-2, Interferon-alpha and 5-Fluorouracil for Patients With High Risk of Relapse After Surgical Treatment for Renal Cell Carcinoma Completed NCT00053807 Phase 3 fluorouracil
44 AE-941 (NEOVASTAT) Versus Placebo in Metastatic Renal Cell Carcinoma Patients Who Are Refractory to Immunotherapy Completed NCT00005995 Phase 3 shark cartilage extract AE-941
45 A Prospective Randomized Phase III Study Comparing Radical Surgery to Elective Kidney Sparing Surgery for Low Stage Renal Cell Carcinoma Completed NCT00002473 Phase 3
46 A RANDOMIZED PHASE II TRIAL OF INTERFERON ALPHA-2A WITH AND WITHOUT 13-CIS RETINOIC ACID IN PATIENTS WITH PROGRESSIVE MEASURABLE METASTATIC RENAL CELL CARCINOMA. Amendment Protocol: Extension to a Randomized Phase III Trial Completed NCT00002737 Phase 3 chemotherapy;isotretinoin
47 SORCE: A Phase III Randomised Double-Blind Study Comparing Sorafenib With Placebo in Patients With Resected Primary Renal Cell Carcinoma at High or Intermediate Risk of Relapse Completed NCT00492258 Phase 3 sorafenib tosylate
48 A Randomized Controlled Trial of Interferon-alpha, Interleukin-2 and 5-Fluorouracil vs. Interferon-alpha Alone in Patients With Advanced Renal Cell Carcinoma Completed NCT00053820 Phase 3 fluorouracil
49 Phase III Randomized Study of Intravenous Low Dose Versus Intravenous High Dose Versus Subcutaneous Interleukin-2 for Metastatic Renal Cell Carcinoma Completed NCT00018941 Phase 3
50 Phase III Randomized Trial of Interferon-Alfa2b Alone Versus Interferon-Alfa2b Plus Thalidomide in Patients With Previously Untreated Metastatic or Unresectable Renal Cell Carcinoma Completed NCT00005966 Phase 3 thalidomide

Search NIH Clinical Center for Kidney Cancer

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Aldesleukin
axitinib
cabozantinib
hydroxyurea
Interferon Alfa-2a
Interferon Alfa-2b
INTERFERON ALFA-3N,HUMAN LEUKOCYTE DERIVED
interferon alfacon-1
Interferon gamma-1b
Interferons
lenvatinib
Lomustine
Medroxyprogesterone
medroxyprogesterone acetate
peginterferon alfa-2a
peginterferon alfa-2b
Recombinant interferon beta-1a
Recombinant interferon beta-1b
sorafenib
sunitinib
sunitinib malate
temsirolimus
Thalidomide
Vinblastine
Vinblastine Sulfate

Cochrane evidence based reviews: kidney neoplasms

Genetic Tests for Kidney Cancer

Anatomical Context for Kidney Cancer

The Foundational Model of Anatomy Ontology organs/tissues related to Kidney Cancer:

19
Kidney

MalaCards organs/tissues related to Kidney Cancer:

40
Kidney, Prostate, Bone, Endothelial, T Cells, Lung, Liver

Publications for Kidney Cancer

Articles related to Kidney Cancer:

(show top 50) (show all 10204)
# Title Authors PMID Year
1
A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity. 61 6
24631838 2014
2
Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy. 61 6
24622468 2014
3
Prospective enterprise-level molecular genotyping of a cohort of cancer patients. 6
25157968 2014
4
The HSP90 inhibitor ganetespib synergizes with the MET kinase inhibitor crizotinib in both crizotinib-sensitive and -resistant MET-driven tumor models. 6
24121490 2013
5
Initial clinical sensitivity and acquired resistance to MET inhibition in MET-mutated papillary renal cell carcinoma. 6
23610116 2013
6
Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma. 6
23213094 2013
7
Differential expression profiling of microRNAs and their potential involvement in renal cell carcinoma pathogenesis. 61 47
19646430 2010
8
Single-agent and combination therapeutic strategies to inhibit hepatocyte growth factor/MET signaling in cancer. 6
18829470 2008
9
Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. 6
11750879 2002
10
Construction of a prognostic value model in papillary renal cell carcinoma by immune-related genes. 42
33761648 2021
11
Tumor microenvironment immune subtypes for classification of novel clear cell renal cell carcinoma profiles with prognostic and therapeutic implications. 42
33725966 2021
12
Clinical significance of prognostic nutritional index in renal cell carcinomas. 42
33725913 2021
13
Multi-modal treatment for metastatic renal cancer: the role of surgery. 61 54
20364382 2010
14
No evidence for a genetic modifier for renal cell cancer risk in HLRCC syndrome. 61 54
20091131 2010
15
The genetic basis of kidney cancer: a metabolic disease. 54 61
20448661 2010
16
Urinary biomarkers for the early diagnosis of kidney cancer. 61 54
20375178 2010
17
Screening for kidney cancer: is there a role for aquaporin-1 and adipophilin? 54 61
20435833 2010
18
Vascular endothelial growth factor polymorphisms: role in response and toxicity of tyrosine kinase inhibitors. 61 54
20425594 2010
19
Influence of osteopontin short hairpin RNA on the proliferation and invasion of human renal cancer cells. 54 61
20155457 2010
20
Molecular basis for the treatment of renal cell carcinoma. 54 61
20080466 2010
21
Compounds in clinical Phase III and beyond. 61 54
20033382 2010
22
Molecular diagnosis and therapy of kidney cancer. 54 61
20059341 2010
23
Systematic sequencing of renal carcinoma reveals inactivation of histone modifying genes. 61 54
20054297 2010
24
Management of vascular endothelial growth factor and multikinase inhibitor side effects. 54 61
19948455 2009
25
In vivo expansion of activated naive CD8+ T cells and NK cells driven by complexes of IL-2 and anti-IL-2 monoclonal antibody as novel approach of cancer immunotherapy. 61 54
19801515 2009
26
The sterol-sensing endoplasmic reticulum (ER) membrane protein TRC8 hampers ER to Golgi transport of sterol regulatory element-binding protein-2 (SREBP-2)/SREBP cleavage-activated protein and reduces SREBP-2 cleavage. 54 61
19706601 2009
27
Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cell-based immunotherapy of metastatic renal cancer. 54 61
19639177 2009
28
VHL loss causes spindle misorientation and chromosome instability. 61 54
19620968 2009
29
Systemic therapy of kidney cancer: tyrosine kinase inhibitors, antiangiogenesis or IL-2? 61 54
19663736 2009
30
TGF-alpha as a candidate tumor antigen for renal cell carcinomas. 54 61
19052740 2009
31
Fumarate hydratase deficiency in renal cancer induces glycolytic addiction and hypoxia-inducible transcription factor 1alpha stabilization by glucose-dependent generation of reactive oxygen species. 61 54
19470762 2009
32
Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial. 61 54
19451442 2009
33
P-glycoprotein activity in renal clear cell carcinoma. 61 54
18440836 2009
34
[Case of drug-induced colitis like ulcerative colitis during IL-2 therapy for multiple bone metastasis after operation of kidney cancer]. 54 61
19663247 2009
35
Phase I trial of metastatic renal cell carcinoma with oral capecitabine and thalidomide. 54 61
19675744 2009
36
The role of antiangiogenesis therapy: bevacizumab and beyond. 54 61
19531449 2009
37
Targeting the Met signaling pathway in renal cancer. 54 61
19496715 2009
38
Treatment of kidney cancer: insights provided by the VHL tumor-suppressor protein. 54 61
19402056 2009
39
Proepithelin is an autocrine growth factor for bladder cancer. 61 54
19237611 2009
40
Hereditary kidney cancer: unique opportunity for disease-based therapy. 54 61
19402075 2009
41
Novel therapeutic inhibitors of the c-Met signaling pathway in cancer. 54 61
19318488 2009
42
High-dose intensity pulse interleukin-2 with famotidine in metastatic kidney cancer. 54 61
19409039 2009
43
mTOR-blocking agents in advanced renal cancer: an emerging therapeutic option. 61 54
19236264 2009
44
[Hereditary renal cancer]. 54 61
19418834 2009
45
Retrospective analysis of the safety and efficacy of interleukin-2 after prior VEGF-targeted therapy in patients with advanced renal cell carcinoma. 54 61
19238017 2009
46
Treatment selection for patients with metastatic renal cell carcinoma: identification of features favoring upfront IL-2-based immunotherapy. 61 54
19165638 2009
47
Implication of bevacizumab in fatal arterial thromboembolic incidents. 61 54
19365880 2009
48
[IL-2 bronchoscopic istillation and immune cell activation: preliminary results of the BRIIL-2 study for treatment of pulmonary metastasis from renal cancer and melanoma]. 61 54
19452104 2009
49
Vascular endothelial growth factor pathway-targeted therapy as initial systemic treatment of patients with renal cancer. 54 61
19891126 2008
50
Kidney cancer: now available in a new flavor. 61 54
19061830 2008

Variations for Kidney Cancer

ClinVar genetic disease variations for Kidney Cancer:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 MET NM_001127500.3(MET):c.3334C>T (p.His1112Tyr) SNV Likely pathogenic 376068 rs121913244 GRCh37: 7:116417463-116417463
GRCh38: 7:116777409-116777409
2 MTOR NM_004958.4(MTOR):c.7514G>C (p.Arg2505Pro) SNV Likely pathogenic 376127 rs1057519777 GRCh37: 1:11169361-11169361
GRCh38: 1:11109304-11109304
3 MTOR NM_004958.4(MTOR):c.6667C>A (p.Gln2223Lys) SNV Likely pathogenic 376128 rs1057519778 GRCh37: 1:11182179-11182179
GRCh38: 1:11122122-11122122
4 MET NM_000245.4(MET):c.3688T>C (p.Tyr1230His) SNV Likely pathogenic 194929 rs121913247 GRCh37: 7:116423413-116423413
GRCh38: 7:116783359-116783359
5 MET NM_000245.4(MET):c.3749T>C (p.Met1250Thr) SNV Likely pathogenic 376126 rs121913245 GRCh37: 7:116423474-116423474
GRCh38: 7:116783420-116783420
6 SDHB NM_003000.3(SDHB):c.572G>A (p.Cys191Tyr) SNV Likely pathogenic 976001 GRCh37: 1:17350538-17350538
GRCh38: 1:17024043-17024043
7 MET NM_000245.4(MET):c.3689A>G (p.Tyr1230Cys) SNV Likely pathogenic 13885 rs121913246 GRCh37: 7:116423414-116423414
GRCh38: 7:116783360-116783360
8 MTOR NM_004958.4(MTOR):c.6644C>A (p.Ser2215Tyr) SNV Likely pathogenic 376129 rs587777894 GRCh37: 1:11184573-11184573
GRCh38: 1:11124516-11124516
9 MET NM_000245.4(MET):c.3281A>G (p.His1094Arg) SNV Likely pathogenic 13887 rs121913243 GRCh37: 7:116417464-116417464
GRCh38: 7:116777410-116777410
10 MTOR NM_004958.4(MTOR):c.4379T>C (p.Leu1460Pro) SNV Likely pathogenic 376130 rs1057519779 GRCh37: 1:11217299-11217299
GRCh38: 1:11157242-11157242

Cosmic variations for Kidney Cancer:

9 (show top 50) (show all 852)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM108082894 XIAP kidney,NS,carcinoma,renal cell carcinoma unclassified c.563G>C p.G188A 23:123886225-123886225 33
2 COSM92179769 XIAP kidney,NS,carcinoma,renal cell carcinoma unclassified c.563G>C p.G188A 23:123886225-123886225 33
3 COSM94289415 XIAP kidney,NS,carcinoma,renal cell carcinoma unclassified c.563G>C p.G188A 23:123886225-123886225 33
4 COSM90652475 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.245G>C p.R82P 3:10142092-10142092 33
5 COSM90649111 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.341-3275A>T p.? 3:10146512-10146512 33
6 COSM88289113 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.341-2A>T p.? 3:10146512-10146512 33
7 COSM90649287 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.217C>T p.Q73* 3:10142064-10142064 33
8 COSM88297043 VHL kidney,NS,carcinoma,renal cell c.485G>T p.C162F 3:10149808-10149808 33
9 COSM90650671 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.341-3261T>C p.? 3:10146526-10146526 33
10 COSM88292918 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.500G>A p.R167Q 3:10149823-10149823 33
11 COSM88288959 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.482G>A p.R161Q 3:10149805-10149805 33
12 COSM88292107 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.256C>T p.P86S 3:10142103-10142103 33
13 COSM90652409 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.234T>G p.N78K 3:10142081-10142081 33
14 COSM88293667 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.548C>A p.S183* 3:10149871-10149871 33
15 COSM90657935 VHL kidney,NS,carcinoma,renal cell c.362G>T p.C121F 3:10149808-10149808 33
16 COSM90649307 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.266T>A p.L89H 3:10142113-10142113 33
17 COSM88289297 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.266T>A p.L89H 3:10142113-10142113 33
18 COSM88290436 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.353T>C p.L118P 3:10146526-10146526 33
19 COSM88292022 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.245G>C p.R82P 3:10142092-10142092 33
20 COSM90653546 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.377G>A p.R126Q 3:10149823-10149823 33
21 COSM88289282 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.217C>T p.Q73* 3:10142064-10142064 33
22 COSM88291948 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.234T>G p.N78K 3:10142081-10142081 33
23 COSM90654329 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.425C>A p.S142* 3:10149871-10149871 33
24 COSM90648957 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.359G>A p.R120Q 3:10149805-10149805 33
25 COSM90652570 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.256C>T p.P86S 3:10142103-10142103 33
26 COSM90667186 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.292T>G p.Y98D 3:10142139-10142139 33
27 COSM88304413 VHL kidney,NS,carcinoma,renal cell carcinoma unclassified c.292T>G p.Y98D 3:10142139-10142139 33
28 COSM85360217 UMPS kidney,NS,carcinoma,renal cell c.528G>A p.L176= 3:124737785-124737785 33
29 COSM136625321 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1152+1G>T p.? 16:2060814-2060814 33
30 COSM101188763 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.584G>T p.C195F 16:2056726-2056726 33
31 COSM90412033 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.2356-1G>C p.? 16:2074199-2074199 33
32 COSM102627070 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1717-1G>C p.? 16:2070455-2070455 33
33 COSM150363299 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.390C>G p.Y130* 16:2054349-2054349 33
34 COSM101182982 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.3136C>T p.R1046* 16:2080179-2080179 33
35 COSM136625326 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1633-1G>T p.? 16:2065518-2065518 33
36 COSM136625708 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.2389-1G>C p.? 16:2074199-2074199 33
37 COSM150363390 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.2356-1G>C p.? 16:2074199-2074199 33
38 COSM151751598 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1600-1G>T p.? 16:2065518-2065518 33
39 COSM136625557 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1009-1G>A p.? 16:2060669-2060669 33
40 COSM102627193 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.975+1G>T p.? 16:2058874-2058874 33
41 COSM150588440 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.541G>A p.V181M 16:2055461-2055461 33
42 COSM148998180 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.541G>A p.V181M 16:2055461-2055461 33
43 COSM151375260 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.731G>T p.C244F 16:2056726-2056726 33
44 COSM148989362 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.976-1G>A p.? 16:2060669-2060669 33
45 COSM101188445 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.972+1G>T p.? 16:2060814-2060814 33
46 COSM149810997 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.390C>G p.Y130* 16:2054349-2054349 33
47 COSM87037342 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.2356-1G>C p.? 16:2074199-2074199 33
48 COSM149804363 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.3280C>T p.R1094* 16:2080179-2080179 33
49 COSM90411912 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.976-1G>A p.? 16:2060669-2060669 33
50 COSM147703838 TSC2 kidney,NS,carcinoma,renal cell carcinoma unclassified c.1600-1G>T p.? 16:2065518-2065518 33

Copy number variations for Kidney Cancer from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 166351 3 10158318 10168746 Mutations VHL Renal cancer

Expression for Kidney Cancer

Search GEO for disease gene expression data for Kidney Cancer.

Pathways for Kidney Cancer

Pathways related to Kidney Cancer according to GeneCards Suite gene sharing:

# Super pathways Score Top Affiliating Genes
1 11.72 MIR27A MIR210 MIR21 MIR200C MIR17 MIR141
2 10.83 MIR27A MIR210 MIR106B
3 10.23 MEG3 HOTAIR

GO Terms for Kidney Cancer

Cellular components related to Kidney Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular vesicle GO:1903561 9.02 MIR27A MIR21 MIR17 MIR126 MIR106B

Biological processes related to Kidney Cancer according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of gene expression GO:0010629 9.84 MIR27A MIR21 MIR17 MIR106B
2 cellular response to hypoxia GO:0071456 9.76 MIR17 MIR126 MIR106B MALAT1
3 positive regulation of vascular smooth muscle cell proliferation GO:1904707 9.65 MIR27A MIR21 MIR17
4 positive regulation of vascular endothelial cell proliferation GO:1905564 9.58 MIR27A MIR21 MIR126
5 positive regulation of endothelial cell differentiation GO:0045603 9.55 MIR21 MIR200C
6 positive regulation of osteoblast differentiation GO:0045669 9.55 MIR27A MIR210 MIR21 MIR200C HIF1A-AS2
7 positive regulation of cytokine production involved in inflammatory response GO:1900017 9.54 MIR21 MIR17 H19
8 negative regulation of low-density lipoprotein particle clearance GO:0010989 9.52 MIR27A MIR17
9 positive regulation of metalloendopeptidase activity GO:1904685 9.51 MIR21 MIR17
10 positive regulation of blood vessel endothelial cell proliferation involved in sprouting angiogenesis GO:1903589 9.5 MIR27A MIR21 MIR126
11 negative regulation of interleukin-1-mediated signaling pathway GO:2000660 9.49 MIR27A MIR21
12 negative regulation of superoxide dismutase activity GO:1901670 9.43 MIR21 H19
13 negative regulation of vascular associated smooth muscle cell apoptotic process GO:1905460 9.43 MIR210 MIR21 MIR17
14 miRNA mediated inhibition of translation GO:0035278 9.43 MIR27A MIR210 MIR21 MIR200C MIR17 MIR106B
15 gene silencing by miRNA GO:0035195 9.32 MIR27A MIR210 MIR21 MIR200C MIR17 MIR141

Molecular functions related to Kidney Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 mRNA 3'-UTR binding GO:0003730 9.5 MIR27A MIR21 MIR200C MIR17 MIR141 MIR126
2 mRNA binding involved in posttranscriptional gene silencing GO:1903231 9.23 MIR27A MIR210 MIR21 MIR200C MIR17 MIR141

Sources for Kidney Cancer

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....